Cargando…

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers

BACKGROUND: Screening for ovarian cancer (OC) in women at high risk consists of a combination of carbohydrate antigen 125 (CA125) and transvaginal ultrasound, despite their low sensitivity and specificity. This could be improved by the combination of several biomarkers, which has been shown in avera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gschwantler-Kaulich, Daphne, Weingartshofer, Sigrid, Rappaport-Fürhauser, Christine, Zeilinger, Robert, Pils, Dietmar, Muhr, Daniela, Braicu, Elena I., Kastner, Marie-Therese, Tan, Yen Y., Semmler, Lorenz, Sehouli, Jalid, Singer, Christian F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731824/ https://www.ncbi.nlm.nih.gov/pubmed/29244844 http://dx.doi.org/10.1371/journal.pone.0189641

Ejemplares similares

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2018)

Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers
por: Rieder, Viktoria, et al.
Publicado: (2015)

Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer
por: Danzinger, Sabine, et al.
Publicado: (2019)

Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients
por: Singer, Christian F., et al.
Publicado: (2019)

Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2017)

CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study
por: Gebhart, P, et al.
Publicado: (2023)

HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2016)

Cadherin-11 expression is upregulated in invasive human breast cancer
por: Pohlodek, Kamil, et al.
Publicado: (2016)

Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?
por: Fotopoulou, Christina, et al.
Publicado: (2012)

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer
por: Dědová, Tereza, et al.
Publicado: (2019)

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer
por: Svoboda, Martin, et al.
Publicado: (2018)

The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
por: Biskup, Karina, et al.
Publicado: (2014)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2014)

Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations
por: Reichl, Florian, et al.
Publicado: (2021)

Patient satisfaction after breast cancer surgery: A prospective clinical trial
por: Leser, Carmen, et al.
Publicado: (2020)

In Situ N-Glycosylation Signatures of Epithelial Ovarian Cancer Tissue as Defined by MALDI Mass Spectrometry Imaging
por: Grzeski, Marta, et al.
Publicado: (2022)

Altered Expression of RB and pRB in Tissue Arrays of Primary Breast Cancers and Matched Axillary Lymph Node Metastases
por: Leser, Carmen, et al.
Publicado: (2022)

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium
por: Pils, Dietmar, et al.
Publicado: (2013)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis
por: Cherif, Soumia, et al.
Publicado: (2021)

Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy
por: Arsenic, Ruza, et al.
Publicado: (2015)

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer
por: Svoboda, Martin, et al.
Publicado: (2016)

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2013)

In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients
por: Kassuhn, Wanja, et al.
Publicado: (2023)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Odén, Lovisa, et al.
Publicado: (2016)

BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers
por: Semmler, Lukas, et al.
Publicado: (2019)

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)
por: Kischkel, Frank Christian, et al.
Publicado: (2017)

Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria
por: Deutschmann, Christine, et al.
Publicado: (2022)

RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers
por: Jones, Wendell D., et al.
Publicado: (2020)

Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer
por: Meshcheryakova, Anastasia, et al.
Publicado: (2019)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer
por: Kreienbring, Katrin, et al.
Publicado: (2016)

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
por: Barnes, Daniel R., et al.
Publicado: (2020)

Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism
por: Niemi, Riikka Johanna, et al.
Publicado: (2018)

Can a morphological description of the peritoneal carcinomatosis in advanced ovarian cancer add prognostic information? Analysis of 1686 patients of the tumor bank ovarian cancer
por: Nasser, Sara, et al.
Publicado: (2022)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells
por: Sun, Pengming, et al.
Publicado: (2018)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_o2d7qapskpj8opmbauf309h1cu